SPONSOR
Sichuan University
Total Trials
3
Recruiting
3
Phases
Phase 2
Conditions studied: Non-Small Cell Lung CancerSmall Cell Lung CancerSmall Cell Lung Cancer Extensive Stage
Sichuan University is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Sichuan University
How many clinical trials has Sichuan University sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Sichuan University, of which 3 are actively recruiting participants. These trials cover conditions including Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Sichuan University research focus on?
Sichuan University clinical trials span Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Sichuan University clinical trial?
To participate in a Sichuan University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sichuan University trials with current recruitment status updated daily.
Clinical Trials by Sichuan University
NCT06951464 Phase 2
Recruiting
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Non-Small Cell Lung Cancer
NCT06769971 Phase 2
Recruiting
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Small Cell Lung Cancer
NCT06610734 Phase 2
Recruiting
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer Extensive Stage
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology